Lisa M Nissen
Overview
Explore the profile of Lisa M Nissen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
644
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malouh M, Cichero J, Sun Y, Lau E, Nissen L, Steadman K
Pharmaceutics
. 2024 Mar;
16(3).
PMID: 38543311
Swallowing oral solid dosage forms is challenging for those who have medication swallowing difficulties, including patients with dysphagia. One option is to mix the drug (whole or crushed) with a...
2.
Malouh M, Sefidani Forough A, Cichero J, Lau E, Nissen L, Steadman K
Aging Med (Milton)
. 2023 Sep;
6(3):239-244.
PMID: 37711253
Objective: To explore the extent of use and perceived effectiveness of using a medication lubricant that is specifically designed to help people who struggle to swallow their solid medications whole....
3.
Shrestha S, Poudel A, Steadman K, Nissen L
Basic Clin Pharmacol Toxicol
. 2023 Jun;
134(1):15-27.
PMID: 37264733
Deprescribing decision making in older adults with limited life expectancy is often challenging for clinicians. We aimed to develop and validate a Deprescribing Tool for Older People with Limited-life Expectancy...
4.
Shrestha S, Poudel A, Forough A, Steadman K, Nissen L
Int J Pharm Pract
. 2022 Dec;
31(1):3-14.
PMID: 36472946
Objectives: A number of deprescribing tools are available to assist clinicians to make decisions on medication management. We aimed to review deprescribing tools that may be used with older adults...
5.
Singleton J, Lau E, Nissen L
Int J Pharm Pract
. 2022 Jun;
30(4):383-390.
PMID: 35716053
Objectives: NHS England has set itself a target of net zero emissions by 2050. Therefore, to address this gap in the literature, this study aimed to explore engagement with NHS...
6.
Shrestha S, Poudel A, Reeve E, Linsky A, Steadman K, Nissen L
Res Social Adm Pharm
. 2022 Mar;
18(9):3596-3601.
PMID: 35296385
Background: Understanding the perspective of health care professionals (HCPs) is significant to the implementation of deprescribing in older adults with limited life expectancy (LLE) but a tool to assess this...
7.
Shrestha S, Poudel A, Cardona M, Steadman K, Nissen L
Ther Adv Drug Saf
. 2021 Oct;
12:20420986211052343.
PMID: 34707802
Introduction: The decision to deprescribe medications used for both disease prevention and symptom control (dual-purpose medications or DPMs) is often challenging for clinicians. We aim to establish the impact of...
8.
Patounas M, Lau E, Chan V, Rigby D, Kyle G, Khatri J, et al.
Pharm Pract (Granada)
. 2021 Aug;
19(3):2376.
PMID: 34457093
Background: In Australia, polypharmacy and medication-related problems are prevalent in the community. Therefore, medicines safety initiatives such as the Home Medicines Review (HMR) service are critical to health care provision....
9.
Singleton J, Lau E, Nissen L
PLoS One
. 2021 Aug;
16(8):e0255445.
PMID: 34407108
Pharmaceuticals and their packaging have a significant negative impact on the environment providing a very strong argument for action on the part of pharmacists and pharmacy technicians to engage with...
10.
Shrestha S, Poudel A, Steadman K, Nissen L
BMJ Open
. 2021 Apr;
11(4):e043766.
PMID: 33795304
Background: Making a meaningful decision on deprescribing of potentially inappropriate medications in older adults with life-limiting illnesses (LLIs) and limited life expectancy (LLE) is often challenging. Therefore, we aimed to...